The aim of this study was to detect changes in intraocular pressure(IOP) following initial intravitreal injection of antivascular endothelial growth factor agents anti-VEGF ranibizumab in patients presenting with macular edema due to diabetes mellitus (DM), age- related macular degeneration(ARMD) , retineal vein occlusion(RVO), and myopic choroidal neovascularization (CNV) .
Methods:In this study,a prospective analysis was conducted on 40 eyes of 40 patients. IOP was measured using a goldmann applanation tonometer before injection, 24 h, 1st and weekly up to 8 weeks after injection . Patients were scheduled for intravitreal injection of anti-VEGF ranibizumab (0.5 mg/0.05 ml) for the treatment of macular edema due to(DM), (RVO), (ARMD) ,and (CNV).
Results: It was fоund that there was a significant difference, but still within the normal range value in IOP measured 24 h after injection(14.2±3.54 mmHg and ranged from (9 : 22 mmHg)) compared to baseline (p = 0.001) . There was no significant difference between the IOP from 1 week up to 8W of ranibizumab injection.
Conclusion: This study confirms the results of previous studies that showed the safety of initial IV injection of anti-VEGF agents for IOP elevation in post-injection two monthes in non- glaucomatous patients.